Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study
Abstract Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib. In this post hoc analysis, we describe the acne even...
Збережено в:
| Автори: | , , , , , , |
|---|---|
| Формат: | Книга |
| Опубліковано: |
Adis, Springer Healthcare,
2023-06-01T00:00:00Z.
|
| Предмети: | |
| Онлайн доступ: | Connect to this object online. |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Інтернет
Connect to this object online.3rd Floor Main Library
| Шифр: |
A1234.567 |
|---|---|
| Примірник 1 | Доступно |